Crinetics Pharmaceuticals Inc’s recently made public that its Chief Med and Dev Officer Pizzuti Dana unloaded Company’s shares for reported $0.64 million on Apr 15 ’24. In the deal valued at $44.47 per share,14,375 shares were sold. As a result of this transaction, Pizzuti Dana now holds 27,786 shares worth roughly $1.23 million.
Then, Struthers Richard Scott sold 40,951 shares, generating $2,013,561 in total proceeds. Upon selling the shares at $49.17, the President & CEO now owns 237,835 shares.
Before that, Okey Stephanie sold 17,500 shares. Crinetics Pharmaceuticals Inc shares valued at $811,650 were divested by the Director at a price of $46.38 per share. As a result of the transaction, Okey Stephanie now holds 6,000 shares, worth roughly $0.27 million.
Citigroup initiated its Crinetics Pharmaceuticals Inc [CRNX] rating to a Buy in a research note published on March 06, 2024; the price target was $68. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid January with a ‘”an Overweight”‘ rating. Jefferies began covering CRNX with “Hold” recommendation on December 21, 2023.
Price Performance Review of CRNX
On Tuesday, Crinetics Pharmaceuticals Inc [NASDAQ:CRNX] saw its stock jump 1.80% to $44.22. Over the last five days, the stock has gained 1.68%. Crinetics Pharmaceuticals Inc shares have risen nearly 24.28% since the year began. Nevertheless, the stocks have risen 147.73% over the past one year. While a 52-week high of $49.58 was reached on 04/04/24, a 52-week low of $15.76 was recorded on 01/05/24. SMA at 50 days reached $42.48, while 200 days put it at $31.57. A total of 0.61 million shares were traded, compared to the trading of 0.47 million shares in the previous session.
Levels Of Support And Resistance For CRNX Stock
The 24-hour chart illustrates a support level at 42.58, which if violated will result in even more drops to 40.95. On the upside, there is a resistance level at 45.32. A further resistance level may holdings at 46.42. The Relative Strength Index (RSI) on the 14-day chart is 50.66, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 71.15%. Stochastics %K at 18.69% indicates the stock is a buying.
